Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration - Wikidata - wikimedia - TriplyDB

Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration

Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration

http://www.wikidata.org/entity/Q37738786

about

Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities Long-term prescribing of new oral anticoagulants Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others?Impact on Drug Safety of Variation in Adherence: The Need for Routinely Reporting Measures of Dose Intensity in Medication Safety Studies Using Electronic Health Data.Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach.Transforming the care of atrial fibrillation with mobile health.Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence Does the association between adherence to statin medications and mortality depend on measurement approach? A retrospective cohort study Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study Adherence to oral anticoagulants in patients with atrial fibrillation-a population-based retrospective cohort study linking health information systems in the Valencia region, Spain: a study protocol.Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study.Innovative designs of point-of-care comparative effectiveness trials.Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study.Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms.The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) : Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands.Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.Target-specific oral anticoagulants and the hospitalist.Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation.Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies.Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation.The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use.Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.Adherence to long-term anticoagulation treatment, what is known and what the future might hold.A Summary of the Literature Evaluating Adherence and Persistence with Oral Anticoagulants in Atrial Fibrillation.Factors Affecting Patients' Perception On, and Adherence To, Anticoagulant Therapy: Anticipating the Role of Direct Oral Anticoagulants.Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.Incorporating Comprehensive Management of Direct Oral Anticoagulants into Anticoagulation Clinics.Patient satisfaction with extended-interval warfarin monitoring.Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients Beliefs about medicines and non-adherence in patients with stroke, diabetes mellitus and rheumatoid arthritis: a cross-sectional study in China Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry).

P2860

Q26787046-17459043-4DC1-449A-860B-F33FB7EC9874 Q28069821-F3B23EA7-0410-49AA-8337-40279D086500 Q28077755-E1FEC201-A649-49C8-A7C0-6A4BFDC3FBB1 Q30994474-B2D31764-9220-41E3-AA9A-88EF59B4F9D0 Q31054764-5657CDAE-D8D6-4731-8A49-74E0AE2FB82B Q33427274-61F0FEF5-C653-459A-9DA4-3740AC506358 Q33449196-F29BB7EE-732F-42D2-9EA0-4DD1779A59E5 Q33553657-8D358D1C-5618-4828-B880-2033C09E94C1 Q33582496-918A1288-26D1-4CD6-B3F4-796E335B81F1 Q34670808-090C5383-4040-4E97-8936-AAD1E0598D39 Q36085794-3EF5CEBC-8E0B-4DE8-915D-E9CC0D0A7877 Q36179688-C986FAED-57B5-4A40-BD6C-1086EC5BB739 Q36217719-7E5761BD-F317-4117-90F4-E22C70C53A10 Q36264914-6B9703E1-82F5-4A63-8D84-A10771EE2F3D Q36352841-028E2962-6632-4CE7-B3FF-C384FE8874B4 Q36571742-54062FA5-F060-4EE3-A38F-A953EB83B4B0 Q36714127-746CE65E-4CE7-4B43-A32E-039503B97115 Q36956791-9F7B823A-D30A-48E2-A5E3-FC44A6D84A28 Q37289894-7CC6E37C-536F-4540-B64B-CB5F2C570FCA Q38262325-D2CB22AE-1D33-4054-A7E7-FCF2BEEDFD74 Q38307541-7E2B6CE1-4463-44B0-8F92-178D29F3894A Q38630768-5D95D58C-CE70-4356-A058-0E94AFF83E1E Q38653946-65CDDD84-F6DF-47F2-B881-CE7EACEE0C26 Q38655829-5E772C20-4BF3-475F-AC4D-F48BAF77F88C Q38655951-012B8F96-47BF-40DA-A6F7-9D4A6CCE1183 Q38662571-81E9A2D8-9DAB-4A01-B28F-EC080574B4AB Q38664920-23A793D8-6F33-4E46-9497-CD7734A563EA Q38723869-4ECCCFC4-87DE-4C49-AD95-910AFAA7103F Q38833151-650BAE88-AC9C-4E81-8FCC-D2B5076521B2 Q38854836-8A1DF2C5-48CC-4A1C-995A-5168CA3A81B2 Q38903357-8B1B2BEE-8BFE-4921-BEEF-5EE09C4C6F25 Q39129273-0789B053-FB55-4247-8DBB-FB11391B430B Q39385409-92347E94-A25D-47FD-9D53-5892B8C64051 Q39449914-8380B4E1-19C9-4BC0-8549-EF6BF8984F40 Q39717056-58375F30-ECFD-4C7C-BABC-A31D485082FB Q40267269-DCD7C463-991C-41B1-9A84-F336A5B64ABF Q41594904-F2EE004A-7B27-48E2-87B5-28D9C36635B2 Q42244714-68A20F6A-4BDF-4373-A7E0-CADB6659360C Q42376801-F589B26F-528C-4A92-A9F6-AE3967FB45B2 Q43630565-C49BC394-DE3D-4D76-A42D-7121091450B7

P2860

Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration

http://www.wikidata.org/entity/Q37738786

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 April 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Adherence to dabigatran therap ...... veterans health administration

@en

Adherence to dabigatran therap ...... eterans health administration.

@nl

type

label

Adherence to dabigatran therap ...... veterans health administration

@en

Adherence to dabigatran therap ...... eterans health administration.

@nl

prefLabel

Adherence to dabigatran therap ...... veterans health administration

@en

Adherence to dabigatran therap ...... eterans health administration.

@nl

P1433

Q37738786-A1013A2D-0D6F-43A3-8DAE-DA9CE13A7B31

P1476

Q37738786-3A229522-BA0B-4287-9B73-11C1C4655AA8

P2093

Q37738786-00458D18-D59C-4498-B4E9-024EA2401EEC

Q37738786-07286DF1-1C67-46E0-884C-20114A758882

Q37738786-15B9AF2C-049C-4376-8589-286C19A146FC

Q37738786-28E57DBC-FED8-46A7-88DE-761FF471A8AE

Q37738786-2FF4A1EA-64F4-4F62-8F08-B30B56CC1F62

Q37738786-34C53169-DF61-4382-9FE0-E94309261693

Q37738786-3E6D71A8-34AA-4C2B-9ECE-91820680388B

Q37738786-4A4FFAC5-0931-4F77-B3E2-CD4216EE9304

Q37738786-6F8237A2-E3BE-424F-853E-353C3ADDAFC3

Q37738786-99C4C335-9347-4DE5-BFA8-5B169C305CC5

P2860

Q37738786-04C35755-7053-42C2-B0FA-C88FCC05D216

Q37738786-0938D0DC-DF51-4D3B-B6C2-63C7FBD84AE4

Q37738786-0AA725A9-23E5-4B7D-986E-F6C5B30D1528

Q37738786-399A2946-E868-430E-9F58-854A825AB8DE

Q37738786-3AF0714B-1ACC-4297-BC57-A9B701E780B5

Q37738786-446A221B-73C1-471D-8375-49E2951E7CA8

Q37738786-4CEF2155-0323-4D38-A32C-4FB5A6A90397

Q37738786-4FDADD71-EED3-43EC-B506-1D2A2ED3D53C

Q37738786-511038DB-3789-438C-919D-F035AB6CAB7B

Q37738786-60D18CA3-0AF2-4D72-B6FE-DF11838E5D7D

P304

Q37738786-17E32E9A-EA31-4D40-820A-7234154ACE06

P31

Q37738786-EBADBE29-10A6-4626-B581-EA9FA96A4D71

P356

Q37738786-C279BE65-2485-4144-ADD0-5A5C0132E5C8

P407

Q37738786-74F8CCC5-CC5C-4FF3-8DBB-7AE07EA2EBF4

P433

Q37738786-46F37CD2-1BA0-4B6B-A7C6-226705186821

P478

Q37738786-2F5953E8-B520-49AF-9C0D-CCEC6CDC6B0E

P50

Q37738786-847DAE22-FC7A-47AA-A357-676A2590B1EA

P577

Q37738786-91C38457-2B0F-4A67-B405-41AE470D7008

P5875

Q37738786-C085FBA7-F1D1-4BC3-A573-244CEC457EA3

P698

Q37738786-207A7BF5-27FE-482C-995B-2D17B011B001

P921

Q37738786-94FF592A-68EF-4209-B416-D88602733CAB

Q37738786-DB6DBD52-6957-4F6B-A39D-07E653A1CBC8

P932

Q37738786-3B6B8570-4DF3-4F4A-8839-C7CA8E6B38F2

P356

J.AHJ.2014.03.023

P1433

American Heart Journal

P1476

Adherence to dabigatran therap ...... veterans health administration

@en

P2093

Anna E Barón

http://www.w3.org/2001/XMLSchema#string

Cynthia A Jackevicius

http://www.w3.org/2001/XMLSchema#string

Evan P Carey

http://www.w3.org/2001/XMLSchema#string

Fran Cunningham

http://www.w3.org/2001/XMLSchema#string

Gary K Grunwald

http://www.w3.org/2001/XMLSchema#string

John S Rumsfeld

http://www.w3.org/2001/XMLSchema#string

Lucas N Marzec

http://www.w3.org/2001/XMLSchema#string

Mintu P Turakhia

http://www.w3.org/2001/XMLSchema#string

P Michael Ho

http://www.w3.org/2001/XMLSchema#string

Paul D Varosy

http://www.w3.org/2001/XMLSchema#string

P2860

Dabigatran versus warfarin in patients with atrial fibrillation

Accuracy and completeness of mortality data in the Department of Veterans Affairs.

A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.

Dabigatran and postmarketing reports of bleeding.

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.

Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database.

A primer and comparative review of major US mortality databases.

Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures.

Evaluating the evidence: is there a rigid hierarchy?

P304

810-817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AHJ.2014.03.023

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

167

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261373235

http://www.w3.org/2001/XMLSchema#string

P698

24890529

http://www.w3.org/2001/XMLSchema#string

P921

P932

5381802

http://www.w3.org/2001/XMLSchema#string